NESS-040C5
From Wikipedia, the free encyclopedia
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
|
|
CAS Number | |
Chemical and physical data | |
Formula | C27H33N3OS |
Molar mass | 447.64 g/mol |
3D model (Jmol) | |
|
NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma.[1] It has reasonable selectivity for the CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related CB1 receptor.[2]
See also[edit]
References[edit]
- ^ Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218
- ^ Hanus LO, Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. Current Medicinal Chemistry. 2010;17(14):1341-59. PMID 20166928
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |